Fluid Therapy in Mechanically Ventilated Critically Ill Adult Patients
Siebe G. Blok, Harm‐Jan de Grooth, Luigi Pisani, Carmen Barbas, Michelle Chew, Arnaldo Dubín, Naomi E. Hammond, Arthur Kwizera, Manu L. N. G. Malbrain, Xavier Monnet, Sheila Nainan Myatra, Louise Rose, Ary Serpa Neto, Zhonghua Shi, Jonathan A. Silversides, Swagata Tripathy, Frank M.P. van Haren, Arjen M. Dondorp, Marcus Josephus Schultz, Niels Van Regenmortel, Frederique Paulus, Pieter Roel Tuinman, PRoFLUID Investigators, Nura Nasser, Melkamu Tilahun, Selina Mutuku, Peter Oduor, Betsy Kirui, Patricia Mwathi, Yugan Dylan Naicker, Nodreen Christine Ayupo, Andrew Kintu, Lameck Ssemwogerere, Betty Khainza, Aggrey Lubikire, Dominic Ogwal, Kenneth Tashobya, Kenneth Nyeko, Michel Vinent Ondwordo, Hajara Nakayiza, Arthur Kisakye, Bruce Bwamiki, Ruth Nasozi, Henry Sserwadda, Michael Mutuma, Edrisa Ssemwanga, Rosephil Koremo, Esther Kitooleko, Innocent Rubangakene, Ian Buyonje and 10 more
Peer-reviewed journalReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Conclusions and Relevance In this prospective international cohort study, fluid therapy varied widely among mechanically ventilated critically ill patients, with maintenance and creep fluids—rather than resuscitation fluids—accounting for most total volume.
We report VG-3927, an oral, CNS-penetrant small-molecule TREM2 agonist that engages the transmembrane domains of TREM2 and its adaptor DAP12 to promote higher-order receptor complex formation and downstream signaling.
Borislav Dejanovic, Matthew D. Figley, Elizabeth F. Weisman and 19 more — Science Translational Medicine
Peer-reviewed journalClaims a big stepReal-world use
Here we present a machine-learning system that predicts clinical trial success across phases I-IV, independently modeling studies with efficacy versus safety/toxicity primary endpoints.
Furthermore, NZEP TA-Ce treatment reverses gut microbiota dysbiosis and optimizes the composition of microbial metabolites, thereby alleviating anxiety and depressive symptoms associated with IBD.
Fan Zhang, Lei Chen, Shengfu Wang and 9 more — Nature Communications
Peer-reviewed journalBold claims, read criticallyReal-world use
ConclusionsAmong critically ill patients with acute kidney injury who had indications for renal-replacement therapy, intermittent hemodialysis as the initial treatment approach was not shown to be noninferior to continuous renal-replacement therapy with respect to major adverse kidney events by day 90 and was associated with higher mortality.
Stèphane Gaudry, Marouane Boubaya, Guillaume Louis and 42 more — New England Journal of Medicine